Recruiting

Heparin vs. Heparin

Sponsor:

Olivier F. Bertrand

Code:

NCT06981624

Conditions

Radial Artery Occlusion

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

No heparin

Study Details

Brief summary:

Randomized study comparing the systematic use of heparin (standard of care) against an elective use of heparin to prevent radial artery occlusion after a percutaneous catheterization using a dual-artery compression system.

Conditions

Radial Artery Occlusion

Study ID

NCT06981624

Start date

May 13, 2025

Status verified date

May, 2025

Completion date

Dec, 2026

Anticipated

Primary completion date

Aug, 2026

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Any patient referred for a diagnostic transradial catheterism

Exclusion Criteria:

  • Unable to understand study design or provide informed consent
  • Unable to receive antiplatelet therapy with aspirina and/or clopidogrel-prasugrel and/or ticagrelor and intravenous anticoagulant derived from heparine or bivalirudine
  • Local condition such as hematoma or pseudo-aneurims precluding radial or ulnar access.
  • Presence of plethysmographic waveform with simultaneous radial and ulnar occlusive compression (due to colaterals or interouseous artery) precluding the evaluation of patent hemostasis.

Study Design

Enrollment

500 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Prevention

Interventions and Outcome Measures

Arms

no intervention: Heparin

Standard of care with 70-100 IU/kg of heparin after a diagnostic only trans-radial catheterization and a dual-artery compression device for hemostasis.

experimental: No heparin

No heparin administered after diagnostic only trans-radial catheterization and a dual-artery compression device for hemostasis.

Interventions

No heparin

Hemostasis achieved using a dual-artery compression device without administration of heparin after trans-radial diagnostic catheterization

Primary outcome measure

  • Rates of patent hemostasis [ Time Frame: within 24 hours after diagnostic angiography ]
  • Time to hemostasis [ Time Frame: within 24 hours post-procedure ]
  • Nursing time involvement [ Time Frame: within 24 hours post-procedure ]
  • Evaluation of complications [ Time Frame: within 30 days of procedure ]

Central Contacts and Locations

Central contacts

Michele Jadin

418-656-8711michele.jadin@criucpq.ulaval.ca

Locations

IUCPQ

Recruiting

Québec, Quebec, Canada, G1V4G5

Contacts

Michele Jadin

4186568711michele.jadin@criucpq.ulaval.ca

More Information

Sponsor

Olivier F. Bertrand

Last update posted

Jan 26, 2026

Last verified

May, 2025

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Olivier F. Bertrand on 2026-01-26.